Sarepta Therapeutics, Inc. (SRPT) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Engine safety override at $20.61: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.8/10. Specifically: High short interest: 28%; Below-average business quality.
Sarepta Therapeutics is a commercial-stage biopharma focused on RNA-targeted and gene therapies for Duchenne muscular dystrophy and other rare neuromuscular diseases, with $1,864.3M in 2025 net product revenues. Its four approved Duchenne products (EXONDYS 51, VYONDYS 53,... Read more
Sell if holding. Engine safety override at $20.61: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.8/10. Specifically: High short interest: 28%; Below-average business quality. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 4.8/10, moderate confidence.
Passes 4/8 gates (clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear). Fails on weak momentum and favorable risk/reward ratio and death cross (50MA < 200MA) and earnings proximity 6d<=7d. Suitability: aggressive.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHSupplierCatalent10-K Item 1: 'Catalent supports our clinical and commercial manufacturing demand for ELEVIDYS and our SRP-9003 LGMD program'
- HIGHSupplierAldevron10-K Item 1: 'Aldevron provides plasmids for ELEVIDYS and SRP-9003'
Material Events(8-K, last 90d)
- 2026-02-25Item 5.02HIGHCEO Douglas Ingram notified Sarepta on Feb 25, 2026 of his decision to retire by end of 2026 or upon appointment of a replacement. Internal and external search commenced. No successor named.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
3 floor-breakers·1 ceiling hit
Unprofitable operations — net margin -32.5%. Quality floor flags this regardless of sector context.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $20.61: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.8/10. Specifically: High short interest: 28%; Below-average business quality. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $19.16. Score 4.8/10, moderate confidence.
Take-profit target: $23.36 (+13.4% upside). Prior stop was $19.16. Stop-loss: $19.16.
Concentration risk — Supplier: Catalent; Concentration risk — Supplier: Aldevron; Target reached (-4.8% upside).
Sarepta Therapeutics, Inc. trades at a P/E of N/A (forward 6.9). TrendMatrix value score: 8.6/10. Verdict: Sell.
33 analysts cover SRPT with a consensus score of 3.4/5. Average price target: $22.
What does Sarepta Therapeutics, Inc. do?Sarepta Therapeutics is a commercial-stage biopharma focused on RNA-targeted and gene therapies for Duchenne muscular...
Sarepta Therapeutics is a commercial-stage biopharma focused on RNA-targeted and gene therapies for Duchenne muscular dystrophy and other rare neuromuscular diseases, with $1,864.3M in 2025 net product revenues. Its four approved Duchenne products (EXONDYS 51, VYONDYS 53, AMONDYS 45, ELEVIDYS) are sold primarily in the U.S.; ELEVIDYS is the key gene therapy growth driver but was suspended for non-ambulatory patients in 2025 due to safety events and ESSENCE trial missed its primary endpoint.